Goldman Sachs’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Goldman Sachs’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-244,200	Closed	-$2.19M	–	7374
2016 Q3	$2.19M	Buy	+244,200	New	+$1.74M	﹤0.01%	3752
2016 Q2	–	Sell	-94,000	Closed	-$432K	–	7576
2016 Q1	$432K	Sell	94,000 -4,600	-5%	-$18.5K	﹤0.01%	4892
2015 Q4	$513K	Buy	98,600 +800	+0.8%	+$4.64K	﹤0.01%	4897
2015 Q3	$592K	Buy	+97,800	New	+$1.2M	﹤0.01%	4973
2015 Q1	–	Sell	-140,800	Closed	-$1.48M	–	7634
2014 Q4	$1.48M	Hold	140,800	–	–	﹤0.01%	4158
2014 Q3	$1.35M	Buy	+140,800	New	+$1.44M	﹤0.01%	4304

Goldman Sachs's RPTP Position: Q4 2016 in Review

Goldman Sachs sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 395,271 shares — an estimated $3.55M sold.

Goldman Sachs first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $44.8M in Q2 2014. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

Goldman Sachs reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
Goldman Sachs sold 395,271 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $3.55M.
Goldman Sachs first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
Goldman Sachs's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $44.8M in Q2 2014.
0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.